Clinical Edge Journal Scan

CRC: Colonoscopy offers a survival benefit over fecal immunochemical test


 

Key clinical point: Compared with fecal immunochemical test (FIT), colonoscopy is a more effective method for improving survival among patients with colorectal cancer (CRC).

Major finding: Compared with no screening, colonoscopy led to a 44% decrease in mortality (adjusted hazard ratio [aHR] 0.56; 95% CI 0.53-0.59), whereas FIT reduced mortality by 22% (aHR 0.78; 95% CI 0.74-0.82).

Study details: This nationwide population-based retrospective study included 24,875 patients with CRC who underwent colonoscopy (n = 9619), FIT (n = 6936), or no screening (n = 8320).

Disclosures: This study was sponsored by the Catholic Medical Center Research Foundation, USA. The authors declared no conflicts of interest.

Source: Sung S-Y et al. Colonoscopy decreases mortality in colorectal cancer patients compared with fecal immunochemical test. J Gastroenterol Hepatol. 2022 (Jun 23). Doi: 10.1111/jgh.15924

Recommended Reading

U.S. hot, cold spots of young-onset CRC may help target interventions
MDedge Hematology and Oncology
Marital status plays modest role in gastric cancer overall survival
MDedge Hematology and Oncology
Life-threatening adverse events in liver cancer less frequent with ICI therapy
MDedge Hematology and Oncology
Barrett’s esophagus: AGA screening update ‘goes above and beyond’
MDedge Hematology and Oncology
Stage II colon cancer: ctDNA-guided approach reduces adjuvant chemotherapy use without compromising recurrence risk
MDedge Hematology and Oncology
Link between Western diet, intestinal microbiota, and CRC: Findings from 2 U.S. cohort studies
MDedge Hematology and Oncology
Stage II/III CRC: 3-month oxaliplatin with 6-month fluoropyrimidine, a promising adjuvant treatment
MDedge Hematology and Oncology
FOLFIRI-bevacizumab tops FOLFIRI-aflibercept in treating metastatic CRC after FOLFOX-bevacizumab failure
MDedge Hematology and Oncology
Efficacy of colonoscopy for preventing CRC remains unaffected by location
MDedge Hematology and Oncology
Cytoreductive surgery + hyperthermic intraperitoneal chemotherapy confers survival benefit in CRC peritoneal metastasis
MDedge Hematology and Oncology